Navigation Links
Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
Date:10/21/2010

ormer Chair of Neuro-Oncology at Memorial Sloan-Kettering Cancer Center commented, "The emerging data from the combination of Xerecept and Avastin is an important development that strongly suggests the need for evaluation of this combination treatment in patients.  Combination therapies are an important part of modern anticancer therapy.  The use of rational combinations of targeted, mechanism-based treatments offers the clinical oncologist the promise of more potent therapeutic options for addressing the multifaceted complexity of cancer."

Celtic Pharma is actively exploring clinical trial strategies to assess combination treatments of Xerecept with Avastin in order to validate these important preclinical findings in a clinical setting, and is also considering the potential for exploring Xerecept in combination with other leading cancer therapies. Celtic Pharma is in productive discussions with the U.S. Food and Drug Administration (FDA) in regards to the design of a registrational study evaluating objectively the clinical benefit associated with reductions in steroid dosing that may be achieved with the use of Xerecept in both primary and metastatic brain tumor patients. Celtic Pharma is also currently evaluating Xerecept in a pediatric trial for patients requiring high doses of corticosteroids to control their cerebral edema, with resulting heavy burdens of steroid-related symptoms.

Preclinical Studies

Several preclinical studies using implanted solid tumor (breast and colon) human xenografts into nude mice, as well as both pediatric and adult human brain tumor xenografts, were evaluated when treated with Xerecept® alone and in combination with Avastin®.  All of these particular models demonstrated statistically significant tumor regression and prolongation of survival following combination treatment with Xerecept and Avastin, compared to Xerecept or Avastin alone.

Specifically, in the human breast model
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
2. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
3. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
4. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
5. Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... A new analysis and infographic released ... Hepatitis C medications could range from hundreds of millions of ... Hepatitis C receive treatment through state programs. The analysis, which ... on public programs, comes at a time when state and ... Gilead Sciences, Harvoni and Sovaldi. ...
(Date:6/30/2015)...  Inari Medical, Inc. announced today that it has ... The financing was led by members of the board ... Venture Partners.  The round also included participation by several ... pleased to complete this financing with the support of ... who joined in February 2015 as President and Chief ...
(Date:6/30/2015)... 30, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical Company focused on the development of oral drug ... been screened in the Company,s Phase IIb trial of ... will be performed under the active Investigational New Drug ... Drug Administration (FDA). The Phase IIb study ...
Breaking Medicine Technology:New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 2New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 3New Analysis Reveals High-Priced Hepatitis C Drugs Could Have Costly Impact on State 4Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 2Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study 3
... Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: ... updated the progress of its Phase II,clinical ... cancer patients who are unable to tolerate ... trial for first-line,treatment of biliary cancer patients. ...
... Late-breaking Phase III,clinical trial data presented today ... Haemostasis (ISTH) Congress demonstrate,that once-daily rivaroxaban achieved ... (VTE) in patients undergoing,knee replacement surgery in ... of care. Patients in the RECORD3,(REgulation of ...
Cached Medicine Technology:Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 2Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 3Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 4Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 5Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:6/30/2015)... ... ... source for last minute tickets for The Rolling Stones at Carter Finley Stadium ... with their 2015 “Zip Code Tour.” , The Stones have been rocking for more than ... of the most beloved songs that this iconic group has performed over the last half ...
(Date:6/30/2015)... ... June 30, 2015 , ... The Blue Cross and Blue Shield of Minnesota ... the state. The projects improve community health by focusing on the social and economic ... are renewable for a second year in 2016 based on progress in 2015. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... Fireside Convalescent Care Center ... The video informs community members of Fireside’s Five-Star Medicare ranking and patient satisfaction. ... seeking care to be well informed and confident about making a decision on ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand ... “Grand Terrace Health Care Center.” Each year, Medicare ranks care centers around the ... best facility for their needs. Grand Terrace prides itself on quality in each ...
(Date:6/30/2015)... Ohio (PRWEB) , ... June 30, 2015 , ... ... services nationwide, announces today that they have been awarded the exclusive billing agreements ... a full range of billing services encompassing their proprietary suite of billing process ...
Breaking Medicine News(10 mins):Health News:The Rolling Stones Tickets in Raleigh at Carter Finley Stadium: Ticket Down Offers Last Minute Tickets for the Rolling Stones and Avett Brothers in Raleigh 2Health News:Blue Cross and Blue Shield of Minnesota Foundation Awards $1.5 Million 2Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2
... Today, the American Hospital Association, Federation of American ... the White House and Senate Finance Chairman Max Baucus ... Cost savings is an important goal, supported by ... physician owned hospitals. As always, physician hospitals will shoulder ...
... ... largest autism science and advocacy organization, launches a new national television advertising campaign calling ... autism. , ... York, NY (PRWEB) July 8, 2009 -- Autism Speaks, the nation,s largest autism science ...
... Mo., July 8 In a new letter ... of Representatives, health reform bill - Ways and Means Chairman ... and Education and Labor Chairman George Miller (D-CA) - the ... legislative discussion draft, as now proposed, could harm seniors, care, ...
... of the future, or at least the way of the ... have increased their use of digital technology. And as ... time and money becomes increasingly important in the practice of ... J. Fasbinder, DDS, MAGD, ABGD will help dentists decrease the ...
... July 8 Healthplace America, Inc., the ... of Robert A. Yungk to Chief Executive Officer. ... and all day-to-day business operations to ensure the success ... , "Healthplace America is an innovative, market driven ...
... ... ... -- Black-and-white movies, eight-track tapes, cassettes--these things are just antiques to most kids. The ... of the past as well, by offering new multimedia tools to fight youth smoking., ...
Cached Medicine News:Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 3Health News:Autism Speaks Launches TV Ad Campaign Calling on Congress to End Insurance Discrimination Against Children with Autism 2Health News:Autism Speaks Launches TV Ad Campaign Calling on Congress to End Insurance Discrimination Against Children with Autism 3Health News:New Letter to Rangel, Waxman, Miller from National Seniors Coalition Outlines Concerns With House Tri-Committee Health Reform Bill 2Health News:New Letter to Rangel, Waxman, Miller from National Seniors Coalition Outlines Concerns With House Tri-Committee Health Reform Bill 3Health News:New Letter to Rangel, Waxman, Miller from National Seniors Coalition Outlines Concerns With House Tri-Committee Health Reform Bill 4Health News:Restoration technology revolutionized 2Health News:Healthplace America Names Robert A. Yungk Chief Executive Officer 2Health News:Healthplace America Names Robert A. Yungk Chief Executive Officer 3Health News:New Tools Help Parents Reinforce Anti-Smoking Message 2
... Stainless steel spiral reinforced. X-ray opaque . Low ... Flange: The flange can be adjusted along the ... cervical soft tissue. The lock ring is turned ... the shaft. Maximum Patient Comfort: The tube is ...
... Per-fit™ tubes are a dual ... of the disposable inner cannula ... provided in the procedural tray. ... tubes are available separately. Per-fit™ ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
Thermosensitivity of material allows tube to conform to patients anatomy for maximum patient comfort....
Medicine Products: